Six High Blood Pressure Clinical Trials Currently Recruiting in the United States

It is essential for clinicians to remain informed about ongoing clinical trial opportunities and resulting data that may inform therapeutic strategies, affect clinical guidelines, expand treatment options, and ultimately improve patient quality of life.

The following six clinical trials are all ongoing, Phase 3, 4 trials in the United States focusing on or related to high blood pressure. All trials are currently recruiting adults with high blood pressure. Additionally, some trials are recruiting for high blood pressure alongside comorbid conditions such as diabetes or cardiovascular disease. Trials are arranged by start date.

Quick View Table of High Blood Pressure Clinical Trials

Currently Recruiting Hypertension Clinical Trials in the United States

A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (NEPHRON)

• Sponsor: Sarfez Pharmaceuticals
• Goal: A study comparing the clinical benefit of finerenone versus a fixed-dose combination (FDC) of extended-release torsemide and spironolactone in patients with hypertension and chronic kidney disease.
• Interventions: FDC of spironolactone and extended-release torsemide, stabilized doses of loop diuretic and finerenone
• Primary Outcome Measures: Comparing net clinical benefit (NBC) of the FDC to finerenone with SBP reduction; Comparing net clinical benefit (NBC) of the FDC to finerenone with UACR reduction; Comparing net clinical benefit (NBC) of the FDC to finerenone with Serum K⁺ reduction.
• Time Frames: 12 weeks; 12 weeks; 12 weeks.
• Study Details 
• Source

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease (ZENITH)

• Sponsor: Alnylam Pharmaceuticals
• Goal: The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events.
• Interventions: Zilebesiran, placebo
• Primary Outcome Measure: Time to first occurrence of a composite endpoint of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) event (hospitalization for HF or urgent HF visit).
• Time Frame: Up to approximately five years.
• Study Details
• Source

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

• Sponsor: Boehringer Ingelheim
• Goal: This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin.
• Interventions: Vicadrostat, empagliflozin, placebo matching vicadrostat
• Primary Outcome Measure: Time to first event of cardiovascular (CV) death or heart failure event (HFE)
• Time Frame: Up to 51 months
• Study Details
• Source

Postpartum Evaluation of Nifedipine and Enalapril for Hypertension (PEACE)

• Sponsor: Nebraska Methodist Health System
• Goal: This is an open label, randomized controlled trial designed to compare nifedipine and enalapril in the management of postpartum hypertension. Investigators will identify and offer enrollment to women who are admitted for delivery with documented hypertension- participants with either chronic hypertension or pregnancy related hypertension will be included.
• Interventions: Enalapril 10mg QD, nifedipine 30mg XL BID
• Primary Outcome Measure: Hospital readmission
• Time Frame: Within six weeks of delivery
• Study Details
• Source

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (BaxDuo-Pacific)

• Sponsor: AstraZeneca
• Goal: To assess efficacy, safety and tolerability of baxdrostat in combination with dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure.
  Interventions: Baxdrostat/dapagliflozin, placebo/dapagliflozin
• Primary Outcome Measure: To determine if baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of the composite endpoint of ≥ 50% sustained decline in eGFR, kidney failure, heart failure events(HF), or CV death.
• Time Frame: Up to 37 months.
• Study Details
• Source

Antihypertensive Mechanisms of Minocycline in Resistant Hypertension

• Sponsor: University of Florida
• Goal: The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension.
• Interventions: Minocycline hydrochloride, placebo
• Primary Outcome Measures: 24-h systolic blood pressure, gut microbiome, gut inflammation and leakiness, neuroinflammation.
• Time Frames: Three months for each primary outcome measure.
• Study Details
• Source

Related Guidelines:

Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

• American College of Cardiology (ACC), American Heart Association (AHA)
• August 2025

Diagnosis and Management of Hypertension (HTN) in Primary Care

• Veterans Health Administration / Department of Defense (VHA/DoD)
• April 2020

Screening and Management of High Blood Pressure in Children and Adolescents

• American Academy of Pediatrics (AAP)
• September 2017

Check out our other trial-focused insights and sign up for alerts and stay informed on the latest published guidelines.